Giacobbe Daniele Roberto, Dettori Silvia, Corcione Silvia, Vena Antonio, Sepulcri Chiara, Maraolo Alberto Enrico, De Rosa Francesco Giuseppe, Bassetti Matteo
Clinica Malattie Infettive, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy.
Department of Health Sciences, University of Genoa, Genoa, Italy.
Infect Drug Resist. 2022 Apr 22;15:2137-2157. doi: 10.2147/IDR.S318322. eCollection 2022.
remains an important human pathogen of concern, with mortality rates surpassing 30% in the case of severe systemic infections. Distinguishing methicillin-susceptible from methicillin-resistant (MRSA) is fundamental for therapeutic choices. A crucial emerging concept in the treatment of acute bacterial skin and skin structure infections is the availability of various approved agents with anti-MRSA activity, which allow a personalized approach based on the characteristics of any given patient while at the same time remaining in line with high certainty efficacy evidence from large randomized controlled trials. Regarding the treatment of bloodstream infections (BSI), interesting aspects that may become relevant in the near future are the presence of both old and novel agents in phase-2 or phase-3 of clinical development for this indication, and the pressing need for high certainty evidence to guide the possible use of combination therapy in specific categories or phenotypes of patients with complicated MRSA BSI.
它仍然是一种令人担忧的重要人类病原体，在严重的全身感染病例中死亡率超过30%。区分甲氧西林敏感菌和耐甲氧西林菌（MRSA）对于治疗选择至关重要。在急性细菌性皮肤和皮肤结构感染的治疗中，一个关键的新兴概念是有多种已获批的具有抗MRSA活性的药物，这使得能够根据任何特定患者的特征采用个性化方法，同时又与大型随机对照试验的高确定性疗效证据保持一致。关于血流感染（BSI）的治疗，在不久的将来可能变得相关的有趣方面包括，针对该适应症处于临床开发2期或3期的既有旧药也有新药，以及迫切需要高确定性证据来指导在复杂MRSA BSI患者的特定类别或表型中可能使用联合治疗。
